Brief: Zyversa Therapeutics CEO Issues Letter To Shareholders Providing Outlook For 2024
03/01/2024 13:10
Jan 3 (Reuters) - Zyversa Therapeutics Inc ZVSA.O :
* ZYVERSA THERAPEUTICS CEO, STEPHEN C. GLOVER, ISSUES LETTER
TO
SHAREHOLDERS PROVIDING OUTLOOK FOR 2024
* ON SCHEDULE TO INITIATE OUR PHASE 2A CLINICAL TRIAL WITH
VAR 200
IN PATIENTS WITH DIABETIC KIDNEY DISEASE IN Q1 OF 2024
* INITIAL DATA OF PHASE 2A CLINICAL TRIAL WITH VAR 200 IN
PATIENTS
WITH DIABETIC KIDNEY DISEASE EXPECTED TO BE AVAILABLE MID-YEAR
* IC 100 PRECLINICAL PROGRAM IS NEARING COMPLETION AND IND
SUBMISSION IS PLANNED FOR Q4 OF 2024
Source text for Eikon: ID:nGNXbQRfk4
Further company coverage: ZVSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zyversa Therapeutics
See all newsBrief: ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million
Brief: ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity
Brief: Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation
Brief: ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status
Brief: Zyversa Therapeutics Files For Prospectus Related To Offer & Resale Of Up To 1.6 Million Shares Of Common Stock By Selling Stockholder - SEC Filing